ARIAD presents clinical proof-of-concept for lung cancer drug
ARIAD Pharmaceuticals has published 'compelling' proof-of-concept data for its new tyrosine-kinase inhibitor AP26113.
ARIAD Pharmaceuticals has published the initial clinical results of its investigational tyrosine-kinase inhibitor AP26113, for patients with advanced non-small cell lung cancer (NSCLC).
Ongoing Phase 1/2 trials indicate that the drug shows compelling anti-tumour activity at a range of dose levels in patients whose tumours are anaplastic lymphoma kinase positive (ALK+).
The research, presented at the European Society for Medical Oncology annual meeting in Austria, is based on the outcomes for 34 patients enrolled in six different cohorts based on dosages of 30, 60, 90, 120, 180 and 240mg - administered in the form of an oral medication once daily.
Currently, 19 remain involved in the study, with 16 of these spread across the three highest dose levels.
"The initial findings from this ongoing study show that AP26113 has impressive anti-tumor activity in ALK+ NSCLC patients, who are either naive or resistant to crizotinib," stated Dr Scott Gettinger, associate professor of medicine at Yale School of Medicine, who prevented the findings at ESMO.
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance